Patent application number | Description | Published |
20090098103 | Modified factor VII polypeptides and uses thereof - Modified factor VII polypeptides and uses thereof are provided. Such modified FVII polypeptides include Factor VIIa and other forms of Factor VII. Among modified FVII polypeptides provided are those that have altered activities, typically altered procoagulant activity, including increased procoagulant activities. Hence, such modified polypeptides are therapeutics. | 04-16-2009 |
20090123452 | Protease screening methods and proteases identified thereby - Methods for identifying modified proteases with modified substrate specificity or other properties are provided. The methods screen candidate and modified proteases by contacting them with a substrate, such as a serpin, an alpha macroglobulins or a p35 family protein or modified serpins and modified p35 family members or modified alpha macroglobulins, that, upon cleavage of the substrate, traps the protease by forming a stable complex. Also provided are modified proteases. | 05-14-2009 |
20090291890 | Factor VII polypeptides that are modified and uses thereof - Modified factor VII polypeptides and uses thereof are provided. Such modified FVII polypeptides include Factor VIIa and other forms of Factor VII. Among modified FVII polypeptides provided are those that have altered activities, typically altered procoagulant activity, including increased procoagulant activities. Hence, such modified polypeptides are therapeutics. | 11-26-2009 |
20100166729 | Modified factor VII polypeptides and uses thereof - Modified factor VII polypeptides and uses thereof are provided. Such modified FVII polypeptides include Factor VIIa and other forms of Factor VII. Among modified FVII polypeptides provided are those that have altered activities, typically altered procoagulant activity, including increased procoagulant activities. Hence, such modified polypeptides are therapeutics. | 07-01-2010 |
20120244139 | Modified proteases that inhibit complement activation - Provided are methods for and compounds for modulating the complement system. In particular, compounds are provided that inhibit complement activation and compounds are provided that promote complement activation. The compounds are therapeutics by virtue of their effects on the complement system. Hence, the compounds that inhibit complement activation can be used for treatment of ischemic and reperfusion disorders, including myocardial infarction and stroke, sepsis, autoimmune diseases, inflammatory diseases and diseases with an inflammatory component, including Alzheimer's Disease and other neurodegenerative disorder. | 09-27-2012 |
20120301945 | PROTEASE SCREENING METHODS AND PROTEASES IDENTIFIED THEREBY - Methods for identifying modified proteases with modified substrate specificity or other properties are provided. The methods screen candidate and modified proteases by contacting them with a substrate, such as a serpin, an alpha macroglobulins or a p35 family protein or modified serpins and modified p35 family members or modified alpha macroglobulins, that, upon cleavage of the substrate, traps the protease by forming a stable complex. Also provided are modified proteases. | 11-29-2012 |
20120308540 | Modified factor IX polypeptides and uses thereof - Modified Factor IX (FIX) polypeptides and uses thereof are provided. Such modified FIX polypeptides include FIXa and other forms of FIX. Among the modified FIX polypeptides provided are those that have altered activities, typically altered procoagulant activity, including increased procoagulant activities. Hence, such modified polypeptides are therapeutics. | 12-06-2012 |
20120308551 | Protease screening methods and proteases identified thereby - Methods for identifying modified proteases with modified substrate specificity or other properties are provided. The methods screen candidate and modified proteases by contacting them with a substrate, such as a serpin, an alpha macroglobulins or a p35 family protein or modified serpins and modified p35 family members or modified alpha macroglobulins, that, upon cleavage of the substrate, traps the protease by forming a stable complex. Also provided are modified proteases. | 12-06-2012 |
20130164820 | PROTEASE SCREENING METHODS AND PROTEASES IDENTIFIED THEREBY - Methods for identifying modified proteases with modified substrate specificity or other properties are provided. The methods screen candidate and modified proteases by contacting them with a substrate, such as a serpin, an alpha macroglobulins or a p35 family protein or modified serpins and modified p35 family members or modified alpha macroglobulins, that, upon cleavage of the substrate, traps the protease by forming a stable complex. Also provided are modified proteases. | 06-27-2013 |
20130177541 | Modified factor IX polypeptides and uses thereof - Modified Factor IX (FIX) polypeptides and uses thereof are provided. Such modified FIX polypeptides include FIXa and other forms of FIX. Among the modified FIX polypeptides provided are those that have altered activities, typically altered procoagulant activity, including increased procoagulant activities. Hence, such modified polypeptides are therapeutics. | 07-11-2013 |
20140030247 | Modified factor X polypeptides and uses thereof - Modified therapeutic proteins are provided. In particular modified Factor X polypeptides, which includes the Factor X zymogen, Factor Xa and other forms of Factor X, and uses thereof are provided. | 01-30-2014 |
20140044701 | Factor VII polypeptides that are modified and uses thereof - Modified factor VII polypeptides and uses thereof are provided. Such modified FVII polypeptides include Factor VIIa and other forms of Factor VII. Among modified FVII polypeptides provided are those that have altered activities, typically altered procoagulant activity, including increased procoagulant activities. Hence, such modified polypeptides are therapeutics. | 02-13-2014 |
20140234290 | MODIFIED FACTOR X POLYPEPTIDES AND USES THEREOF - Modified therapeutic proteins are provided. In particular modified Factor X polypeptides, which includes the Factor X zymogen, Factor Xa and other forms of Factor X, and uses thereof are provided. | 08-21-2014 |
20140242062 | MODIFIED PROTEASES THAT INHIBIT COMPLEMENT ACTIVATION - Provided are methods for and compounds for modulating the complement system. In particular, compounds are provided that inhibit complement activation and compounds are provided that promote complement activation. The compounds are therapeutics by virtue of their effects on the complement system. Hence, the compounds that inhibit complement activation can be used for treatment of ischemic and reperfusion disorders, including myocardial infarction and stroke, sepsis, autoimmune diseases, inflammatory diseases and diseases with an inflammatory component, including Alzheimer's Disease and other neurodegenerative disorders. | 08-28-2014 |
20140322191 | MODIFIED FACTOR IX POLYPEPTIDES AND USES THEREOF - Modified Factor IX (FIX) polypeptides and uses thereof are provided. Such modified FIX polypeptides include FIXa and other forms of FIX. Among the modified FIX polypeptides provided are those that have altered activities, typically altered procoagulant activity, including increased procoagulant activities. Hence, such modified polypeptides are therapeutics. | 10-30-2014 |
Patent application number | Description | Published |
20100179919 | Student venture management - A technique involves providing an actual cost commitment and investing a retail value of the actual cost commitment to a student venture, and receiving a return on the retail value and a return on actual cost that is equal to the return on the retail value minus the actual cost commitment. A system constructed according to the technique may include an investment decision engine, a portfolio management engine, and a venture scholar fund operations engine. The system may further include, for example, an authentication engine and a public information engine. | 07-15-2010 |
20110167019 | Venture capital transaction with a university scholarship - A technique involves providing an actual cost commitment and investing a retail value of the actual cost commitment to a student venture, and receiving a return on the retail value and a return on actual cost that is equal to the return on the retail value minus the actual cost commitment. A system constructed according to the technique may include an investment decision engine, a portfolio management engine, and a venture scholar fund operations engine. The system may further include, for example, an authentication engine and a public information engine. | 07-07-2011 |
20130246309 | Student Venture Management - A technique involves providing an actual cost commitment and investing a retail value of the actual cost commitment to a student venture, and receiving a return on the retail value and a return on actual cost that is equal to the return on the retail value minus the actual cost commitment. A system constructed according to the technique may include an investment decision engine, a portfolio management engine, and a venture scholar fund operations engine. The system may further include, for example, an authentication engine and a public information engine. | 09-19-2013 |
20140324733 | STUDENT VENTURE MANAGEMENT - A technique involves: receiving authentication information for a team leader at an authentication engine; storing a venture scholarship application data structure in a new applications data store; storing credentials of the team leader in association with the venture scholarship application data structure; building a student venture team at a venture scholar networking engine; storing credentials of members of the student venture team in association with the venture scholarship application data structure; allocating financial support associated with the venture scholarship after the venture scholarship is indicated to be eligible by an eligibility filtering engine; recording equity or an instrument convertible to equity in a student venture associated with the student venture team and the venture scholarship at a student venture fund operations engine; allocating equity or the instrument convertible to equity from the student venture to members working on the student venture as the student venture matures. | 10-30-2014 |
Patent application number | Description | Published |
20120215398 | Diagnostic Process for Home Electronic Devics - A method of processing system diagnostic data is provided for identifying likely device fix(s) associated with a diagnostic data, and identifying a repair procedure(s) for correcting the likely fix(s). The process receiving diagnostic data from a system onboard computer at a remote diagnostic database, the database being arranged to map system diagnostic data to possible vehicle fix(s). The possible device fix(s) are prioritized in accordance with ranked matches of the received diagnostic data to combinations of diagnostic data stored in a prior experience database. The prior experience database having an identified fix associated with each stored combination of diagnostic data. The fix associated with the highest ranked combination of diagnostic data is identified as the most likely fix. The most likely fix is mapped to a system repair database, the most likely fix being directly mapped to an associated repair procedure for repairing the most likely fix. | 08-23-2012 |
20130204485 | Handheld Scan Tool with Fixed Solution Capability - A diagnostic scan tool is provided including a connect/configure module for establishing a communication link between the scan tool and a vehicle electronic control unit (ECU). A vehicle specification module operates to identify a vehicle under test in response to receipt of a vehicle identification number (VIN). A trouble code module receives digital trouble codes (DTCs) from the ECU. A freeze frame data module retrieves freeze frame data from the ECU, the retrieved freeze frame data being functionally associated with a highest priority DTC. A database lists possible vehicle defect solutions, indexed to the VIN and the DTCs. A digital signal processor is operative to derive the highest priority DTC from analysis of the retrieved freeze frame data. The digital signal processor further being operative to regulate selection of a most likely vehicle defect solution associated with the VIN and the highest priority DTC. | 08-08-2013 |
20130297143 | METHOD OF PROCESSING VEHICLE DIAGNOSTIC DATA - A method of processing vehicle diagnostic data is provided for identifying likely vehicle fix(s) associated with a diagnostic data, and identifying a repair procedure(s) for correcting the likely fix(s). The process receiving vehicle diagnostic data from a vehicle onboard computer at a remote diagnostic database, the database being arranged to map vehicle diagnostic data to possible vehicle fix(s). The possible vehicle fix(s) are prioritized in accordance with ranked matches of the received diagnostic data to combinations of diagnostic data stored in a prior experience database. The prior experience database having an identified fix associated with each stored combination of diagnostic data. The fix associated with the highest ranked combination of diagnostic data is identified as the most likely fix. The most likely fix is mapped to a vehicle repair database, the most likely fix being directly mapped to an associated repair procedure for repairing the most likely fix. | 11-07-2013 |
20140052328 | Predictive Diagnostic Calculation - There is provided a method of predicting defects likely to occur in a vehicle over a predetermined period. The method includes receiving vehicle characteristic data regarding a vehicle under consideration, and comparing the received vehicle characteristic data with a defect database. The defect database includes information related to defects that have occurred in different vehicles and the mileage at which such defects occurred. The method additionally includes identifying defects that occurred in vehicles corresponding to use vehicle under consideration, and the mileage at which such defects occurred. Detects which fail to satisfy minimum count requirements are then filtered out, and the defects are then sorted in order of the highest defect count. | 02-20-2014 |
20140188329 | METHOD AND SYSTEM FOR DETERMINING THE LIKELY OPERATING COST FOR A PARTICULAR TYPE OF VEHICLE OVER A DEFINED PERIOD - A method is disclosed for determining the cost of operating a vehicle over a defined period of time. The method proceeds by establishing, on a database, a schedule of anticipated future repairs for a plurality of vehicle types, the repair schedule including the cost of the repairs and the approximate mileage at which the anticipated future repair(s) are expected to become necessary. A processor, in communication with the database, receives information identifying a particular of vehicle, and the present mileage associated with that particular vehicle. Using the vehicle type information, the vehicle's present mileage information and the repair schedule, the processor then computes the approximate total future repair costs for maintaining the vehicle over a defined period of time. | 07-03-2014 |
20140195101 | Multi-Stage Diagnostic System and Method - A multi-stage diagnostic system and related method which seeks diagnostic information from a secondary information source when a first information source does not yield sufficient data for producing a diagnostic result. In particular, diagnostic process includes a first stage of communicating with an onboard vehicle computer to retrieve diagnostic trouble codes therefrom. If diagnostic trouble codes are received from the onboard computer, the diagnostic trouble codes are used to produce a diagnostic result. On the other hand, if no diagnostic trouble codes are retrieved from the onboard computer, the diagnostic process proceeds to a second stage wherein symptomatic diagnostic information is solicited from the user. A series of symptomatic questions may be presented to the user on a smartphone. | 07-10-2014 |
20150105972 | HAND HELD DATA RETRIEVAL DEVICE WITH FIXED SOLUTION CAPABILITY - A diagnostic scan tool is provided including a connect/configure module for establishing a communication link between the scan tool and a vehicle electronic control unit (ECU). A vehicle specification module operates to identify a vehicle under test in response to receipt of a vehicle identification number (VIN). A trouble code module retrieves digital trouble codes (DTCs) from the ECU. A freeze frame data module retrieves freeze frame data from the ECU, the retrieved freeze frame data being functionally associated with a highest priority DTC. A database lists possible vehicle defect solutions, indexed to the VIN and the DTCs. A digital signal processor is operative to derive the highest priority DTC from analysis of the retrieved freeze frame data. The digital signal processor further being operative to regulate selection of a most likely vehicle defect solution associated with the VIN and the highest priority DTC. | 04-16-2015 |
Patent application number | Description | Published |
20100137326 | NOVEL 4-CYANO, 4-AMINO, AND 4-AMINOMETHYL DERIVATIVES OF PYRAZOLO[1,5-a]PYRIDINES, PYRAZOLO[1,5-c]PYRIMIDINES AND 2H-INDAZOLE COMPOUNDS AND 5-CYANO, 5-AMINO, AND 5-AMINOMETHYL DERIVATIVES OF IMIDAZO[1,2-a]PYRIDINES, AND IMIDAZO[1,5-a]PYRAZINES AS CYCLIN DEPENDENT KINASE INHIBITORS - In its many embodiments, the present invention provides a novel class of 4-cyano, 4-amino, and 4-aminomethyl derivatives of pyrazolo[1,5-a]pyridine, pyrazolo[1,5-c]pyrimidine, and 2H-Indazole compounds and 5-cyano, 5-amino, and 5-aminomethyl derivatives of imidazo[1,2-a]pyridine and imidazo[1,5-a]pyrazine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions. | 06-03-2010 |